Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-controlled, non-randomized study to investigate the long-lasting
radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluate
response to 177Lu-DOTAEB-TATE in patients with advanced metastatic neuroendocrine tumors.
Different groups with doses of 0.37GBq-0.74GBq (10-20 mCi) and 1.85GBq (50 mCi)of
177Lu-DOTA-EB-TATE,3.7GBq (100 mCi)of 177Lu-DOTA-TATE will be injected intravenously. All
patients will undergo 68Ga-DOTATATE PET/CT scans before and after the treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Treatments:
(177)Lu-DOTA-EB-TATE 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid Lutetium Lu 177 dotatate Octreotide